GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valbiotis SA (XPAR:ALVAL) » Definitions » Investments And Advances

Valbiotis (XPAR:ALVAL) Investments And Advances : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Valbiotis Investments And Advances?

Valbiotis's Investments And Advances for the quarter that ended in Dec. 2023 was €0.00 Mil.


Valbiotis Investments And Advances Historical Data

The historical data trend for Valbiotis's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valbiotis Investments And Advances Chart

Valbiotis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Investments And Advances
Get a 7-Day Free Trial Premium Member Only - - - - -

Valbiotis Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Valbiotis Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Valbiotis (XPAR:ALVAL) Business Description

Traded in Other Exchanges
Address
12F rue Paul VATINE, Perigny, La Rochelle, FRA, 17180
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of major metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.

Valbiotis (XPAR:ALVAL) Headlines

No Headlines